Hidradenitis Suppurativa Hurley Stage II (Investigational Adjunct)

Investigational adjunct in Hurley Stage II HS refractory to conventional therapy; case reports only; biologics (adalimumab, secukinumab) and surgical management remain primary.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?: Not FDA-cleared for Hidradenitis Suppurativa Hurley Stage II. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
¿Qué evidencia existe?: Tier C (investigational). Hurley Stage II HS has recurrent abscesses with sinus tracts. Evidence-based first-line management is adalimumab (FDA-approved for moderate-to-severe HS), secukinumab (FDA-approved 2023), oral tetracyclines, oral clindamycin plus rifampin, and surgical de-roofing or wide excision of sinus tracts. Leech therapy here is highly investigational and should never replace these proven options.
Riesgos principales: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Triggering or worsening an active abscess
Seeding leech bacteria into existing sinus tracts and abscess cavities
Compounding scarring on already scarred and disfiguring skin
Quién no debería considerar esto: Patients with an actively fluctuant abscess (incision and drainage first)
Patients who have not had a trial of adalimumab, secukinumab, or oral antibiotic combinations
Patients with multiple interconnected sinus tracts (likely need surgical de-roofing or wide excision instead)
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
Qué preguntar a su clínico: Has biologic therapy (adalimumab, secukinumab) been tried — these are FDA-approved for HS?
Have I tried oral clindamycin plus rifampin or other established oral regimens?
Should surgical de-roofing or wide excision be considered for the sinus tracts?
What is the published evidence base for leeches in Hurley II HS specifically?
How will infection risk be managed given existing sinus tracts and abscesses?
What scarring outcome should I expect on top of existing HS scarring?
Cuándo buscar atención urgente: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
Rapidly expanding redness, severe pain, fever, or red streaks (possible cellulitis or sepsis)
Sudden purulent drainage with surrounding warmth and systemic symptoms
Difficulty moving the affected area (axilla, groin) due to severe pain or swelling

Qué NO significa esto

It does not mean leech therapy is FDA-cleared for HS — the only FDA clearance for medicinal leeches is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace adalimumab or secukinumab, which ARE FDA-approved for HS.
It does not address the chronic follicular occlusion and inflammation driving HS.
It does not prevent progression to Hurley Stage III.
It does not have controlled-trial evidence and may worsen existing scarring.

Referencias cruzadas de seguridad

Clinical Profile

Category: dermatological
ICD-10: L73.2
Safety tier: high

Evidence Summary

Hidradenitis suppurativa management per the North American HS Clinical Management Guidelines includes lifestyle modification, topical and systemic antibiotics (clindamycin-rifampin), hormonal therapy in selected patients, biologics (adalimumab FDA-approved 2015, secukinumab FDA-approved 2023), and surgical excision for Hurley Stage II/III. No controlled clinical trial supports leech therapy for HS; the only published clinical report documents harm, describing a foreign-body granuloma complicated by lymphedema after leech therapy. Critical safety: HS lesions are inflammatory and tunnel-forming; direct leech application to active sinus tracts risks dissemination and Aeromonas superinfection. Leech therapy for HS should be regarded as contraindicated rather than beneficial. Evidence is grade D.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Wollina U (2010)0

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Hurley Stage III with extensive tunneling (surgical management preferred)
Active sinus tract drainage or abscess (drain first)
Concurrent TNF-alpha inhibitor with infection risk
MRSA colonization with recent superinfection
Diabetic foot syndrome or peripheral neuropathy

Related Conditions

Livedo Reticularis

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

Lipodermatosclerosis

Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.

Insulin Injection Lipohypertrophy

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.